NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03897881,An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942),https://clinicaltrials.gov/study/NCT03897881,,RECRUITING,The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.,NO,Melanoma,DRUG: mRNA-4157|BIOLOGICAL: Pembrolizumab,"Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging, RFS is defined as the time between the date of first dose of pembrolizumab and the date of recurrence (local, regional, or distant metastasis), new primary melanoma, or death (whatever the cause), whichever occurs first., Up to 5 years","Distant Metastasis-Free Survival (DMFS), Assessed Using Radiological Imaging, DMFS is defined as the time between the date of first dose of pembrolizumab and the date of the first distant metastasis or the date of death (whatever the cause), whichever occurs first., Up to 5 years|Number of Participants With Adverse Events (AEs), Baseline through 100 days after last mRNA-4157 dose (for mRNA-4157 and Pembrolizumab combination arm) and up to 90 days after last pembrolizumab dose (for Pembrolizumab only arm) (up to a total of 5 years for both arms)|Number of Participants Who Discontinued Due to AEs, Baseline through 100 days after last mRNA-4157 dose (for mRNA-4157 and Pembrolizumab combination arm) and up to 90 days after last pembrolizumab dose (for Pembrolizumab only arm) (up to a total of 5 years for both arms)",,"ModernaTX, Inc.",Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,267,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,mRNA-4157-P201,2019-07-18,2029-09-09,2029-09-09,2019-04-01,,2025-03-25,"University of Arizona, Tucson, Arizona, 85719, United States|California Pacific Medical Center Research Institute -CPMCRI, San Francisco, California, 94115, United States|Angeles Clinic and Research Institute, Santa Monica, California, 90404, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Smilow Cancer Center at Yale New Haven Hospital, New Haven, Connecticut, 06520, United States|Lombardi Cancer Center, Washington, District of Columbia, 20007, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, 32806, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|UPMC Hillman Cancer Center, Chicago, Illinois, 60637, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|NYU Langone Medical Center, New York, New York, 10016, United States|Providence Cancer Institute, Portland, Oregon, 97213, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States|Texas Oncology PA, Dallas, Texas, 75246, United States|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Affinity Clinical Research, Murdoch, Western Australia, 6150, Australia|St John of God Hospital Subiaco, Subiaco, Western Australia, 6008, Australia",
